tailieunhanh - Báo cáo y học: " Defining human mesenchymal stem cell efficacy in vivo"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Defining human mesenchymal stem cell efficacy in vivo. | Bonfield et al. Journal of Inflammation 2010 7 51 http content 7 1 51 RESEARCH JOURNAL OF INFLAMMATION Open Access Defining human mesenchymal stem cell efficacy in vivo Tracey L Bonfield1 Mary T Nolan Koloze 1 Donald P Lennon2 Arnold I Caplan2 Abstract Allogeneic human mesenchymal stem cells hMSCs can suppress graft versus host disease GvHD and have profound anti-inflammatory and regenerative capacity in stroke infarct spinal cord injury meniscus regeneration tendinitis acute renal failure and heart disease in human and animal models of disease. There is significant clinical hMSC variability in efficacy and the ultimate response in vivo. The challenge in hMSC based therapy is defining the efficacy of hMSC in vivo. Models which may provide insight into hMSC bioactivity in vivo would provide a means to distinguish hMSCs for clinical utility. hMSC function has been described as both regenerative and trophic through the production of bioactive factors. The regenerative component involves the multi-potentiality of hMSC progenitor differentiation. The secreted factors generated by the hMSCs are milieu and injury specific providing unique niches for responses in vivo. These bioactive factors are anti-scarring angiogenic anti-apoptotic as well as regenerative. Further from an immunological standpoint hMSC s can avoid host immune response providing xenographic applications. To study the in vivo immuno-regulatory effectiveness of hMSCs we used the ovalbumin challenge model of acute asthma. This is a quick 3 week in vivo pulmonary inflammation model with readily accessible ways of measuring effectiveness of hMSCs. Our data show that there is a direct correlation between the traditional ceramic cube score to hMSCs attenuation of cellular recruitment due to ovalbumin challenge. The results from these studies verify the in vivo immuno-modulator effectiveness of hMSCs and support the potential use of the ovalbumin model as an in vivo model of hMSC .